Composite

Part:BBa_K2923021:Experience

Designed by: Kateryna LEN   Group: iGEM19_Strasbourg   (2019-10-13)
Revision as of 18:32, 16 October 2019 by Katya (Talk | contribs) (In-vitro assay of BBa_K2923021)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Introduction

To validate the designed constructs we decided to test Guanine switch-on (active auto-cleavage in the presence of ligand). For negative control, we choose an inactive form of aptazyme: mutation at the ribozyme domain. iGEM Strasbourg designed construct requires the use of aptazyme linked to MS2 and PP7 stem-loops. The following results described MS2-MS2-Aptazyme-PP7-PP7 activity in in-vitro and in-vivo assays.

In-vitro assay of BBa_K2923021

In order to check MS2-MS2-Guanine-PP7-PP7 cleavage activities, in-vitro transcription products were analyzed by 2% agarose gel with urea (Figure 1).

Figure 1: Aptazyme catalytic activity assay. Guanine aptazyme were transcribed in vitro for 1h30. RNA was analyzed in an 8% polyacrylamide gel with urea. The inactive form of Guanine aptazyme represents the whole RNA and corresponds to the band of 138 pb. Cleaved aptazyme represents the two parts of the aptazyme Guanine (28 pb + 110 pb).

Inactive aptazyme did not present aptazyme catalytic activity, which confirms their use as an efficient negative control.

To see in-vivo assays results of MS2-MS2-Guanine-PP7-PP7 aptazymes see BBa_K2923020.

User Reviews

UNIQ668eaed5acd63354-partinfo-00000001-QINU UNIQ668eaed5acd63354-partinfo-00000002-QINU